These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
453 related items for PubMed ID: 29855112
1. Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq® (human-cl rhFVIII) in previously treated patients with severe haemophilia A. Dargaud Y, Negrier C, Rusen L, Windyga J, Georgiev P, Bichler J, Solomon C, Knaub S, Lissitchkov T, Klamroth R. Haemophilia; 2018 Jul; 24(4):619-627. PubMed ID: 29855112 [Abstract] [Full Text] [Related]
2. PK-guided personalized prophylaxis with Nuwiq® (human-cl rhFVIII) in adults with severe haemophilia A. Lissitchkov T, Rusen L, Georgiev P, Windyga J, Klamroth R, Gercheva L, Nemes L, Tiede A, Bichler J, Knaub S, Belyanskaya L, Walter O, Pasi KJ. Haemophilia; 2017 Sep; 23(5):697-704. PubMed ID: 28452151 [Abstract] [Full Text] [Related]
3. Long-term tolerability, immunogenicity and efficacy of Nuwiq® (human-cl rhFVIII) in children with severe haemophilia A. Klukowska A, Szczepański T, Vdovin V, Knaub S, Bichler J, Jansen M, Dzhunova I, Liesner RJ. Haemophilia; 2018 Jul; 24(4):595-603. PubMed ID: 29582516 [Abstract] [Full Text] [Related]
4. Prophylaxis vs. on-demand treatment with Nuwiq(®) (Human-cl rhFVIII) in adults with severe haemophilia A. Tiede A, Oldenburg J, Lissitchkov T, Knaub S, Bichler J, Manco-Johnson MJ. Haemophilia; 2016 May; 22(3):374-80. PubMed ID: 26582282 [Abstract] [Full Text] [Related]
5. A new paradigm for personalized prophylaxis for patients with severe haemophilia A. Delavenne X, Ollier E, Lienhart A, Dargaud Y. Haemophilia; 2020 Mar; 26(2):228-235. PubMed ID: 32100950 [Abstract] [Full Text] [Related]
6. Efficacy and safety of Nuwiq® (human-cl rhFVIII) in patients with severe haemophilia A undergoing surgical procedures. Zozulya N, Kessler CM, Klukowska A, von Depka M, Hampton K, Hay CRM, Jansen M, Bichler J, Knaub S, Rangarajan S. Haemophilia; 2018 Jan; 24(1):70-76. PubMed ID: 29048712 [Abstract] [Full Text] [Related]
14. Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A. Chowdary P, Mullins ES, Konkle BA, McGuinn C, Park YS, Stasyshyn O, Zulfikar B, Engl W, Tangada S. Haemophilia; 2020 Jul; 26(4):e168-e178. PubMed ID: 32597029 [Abstract] [Full Text] [Related]
15. Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial. Lentz SR, Janic D, Kavakli K, Miljic P, Oldenburg J, C Ozelo M, Santagostino E, Suzuki T, Zupancic Šalek S, Korsholm L, Matytsina I, Tiede A. Haemophilia; 2018 Nov; 24(6):e391-e394. PubMed ID: 30402994 [Abstract] [Full Text] [Related]
16. Pharmacokinetic-guided prophylaxis improved clinical outcomes in paediatric patients with severe haemophilia A. Huang K, Zhen Y, Li G, Wu X, Chen Z, Wu R. Haemophilia; 2021 Jul; 27(4):e450-e457. PubMed ID: 34015176 [Abstract] [Full Text] [Related]